Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study

IF 6.1 2区 医学 Q1 ONCOLOGY
Cancer Pub Date : 2024-07-10 DOI:10.1002/cncr.35476
Yating Wang MD, Kyle Kondrat DO, Janak Adhikari MD, Quynh Nguyen MD, Qian Yu MD, Dipesh Uprety MD
{"title":"Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study","authors":"Yating Wang MD,&nbsp;Kyle Kondrat DO,&nbsp;Janak Adhikari MD,&nbsp;Quynh Nguyen MD,&nbsp;Qian Yu MD,&nbsp;Dipesh Uprety MD","doi":"10.1002/cncr.35476","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>In 2015, the US Food and Drug Administration approved nivolumab as the first immunotherapy for patients with advanced non–small cell lung cancer (NSCLC). However, population-based survival benefit studies after the introduction of immunotherapy in lung cancer are lacking. This study examined overall survival (OS) and cancer-specific survival in patients with NSCLC in the pre immunotherapy and immunotherapy eras.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study used the Surveillance, Epidemiology, and End Results database, which spanned 17 registries from 2000 to 2020. Two cohorts were delineated: preimmunotherapy (2010–2014) and immunotherapy (2015–2020), which coincided with nivolumab’s approval.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This study included 191,802 patients, 90,807 in the preimmunotherapy era and 100,995 in the immunotherapy era. OS was significantly higher in the immunotherapy era, as shown by Kaplan–Meier curves (1-year OS, 40.1% vs. 33.5%; 3-year OS, 17.8% vs. 11.7%; 5-year OS, 10.7% vs. 6.8%; median OS, 8 vs. 7 months; <i>p</i> &lt; .001 by log-rank test). Similarly, cancer-specific survival improved in the immunotherapy era (1-year survival, 44.0% vs. 36.8%; 3-year survival, 21.7% vs. 14.4%; 5-year survival, 14.3% vs. 9.0%; median OS, 10 vs. 8 months; <i>p</i> &lt; .001 by log-rank test). Survival rates were significantly better in the immunotherapy era, as confirmed by multivariate analysis with a Cox proportional hazards model after adjusting for age, sex, race, income, and geographical area (adjusted hazard ratio, 0.830; 95% CI, 0.821–0.840; <i>p</i> &lt; .001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>In summary, the survival rate of patients with metastatic NSCLC has improved since the introduction of immunotherapy.</p>\n </section>\n </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 1","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cncr.35476","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

In 2015, the US Food and Drug Administration approved nivolumab as the first immunotherapy for patients with advanced non–small cell lung cancer (NSCLC). However, population-based survival benefit studies after the introduction of immunotherapy in lung cancer are lacking. This study examined overall survival (OS) and cancer-specific survival in patients with NSCLC in the pre immunotherapy and immunotherapy eras.

Methods

This study used the Surveillance, Epidemiology, and End Results database, which spanned 17 registries from 2000 to 2020. Two cohorts were delineated: preimmunotherapy (2010–2014) and immunotherapy (2015–2020), which coincided with nivolumab’s approval.

Results

This study included 191,802 patients, 90,807 in the preimmunotherapy era and 100,995 in the immunotherapy era. OS was significantly higher in the immunotherapy era, as shown by Kaplan–Meier curves (1-year OS, 40.1% vs. 33.5%; 3-year OS, 17.8% vs. 11.7%; 5-year OS, 10.7% vs. 6.8%; median OS, 8 vs. 7 months; p < .001 by log-rank test). Similarly, cancer-specific survival improved in the immunotherapy era (1-year survival, 44.0% vs. 36.8%; 3-year survival, 21.7% vs. 14.4%; 5-year survival, 14.3% vs. 9.0%; median OS, 10 vs. 8 months; p < .001 by log-rank test). Survival rates were significantly better in the immunotherapy era, as confirmed by multivariate analysis with a Cox proportional hazards model after adjusting for age, sex, race, income, and geographical area (adjusted hazard ratio, 0.830; 95% CI, 0.821–0.840; p < .001).

Conclusions

In summary, the survival rate of patients with metastatic NSCLC has improved since the introduction of immunotherapy.

免疫疗法在美国获批前后转移性非小细胞肺癌患者的生存趋势:基于监测、流行病学和最终结果数据库的研究。
背景:2015 年,美国食品和药物管理局批准 nivolumab 作为首个免疫疗法用于晚期非小细胞肺癌(NSCLC)患者。然而,在肺癌中引入免疫疗法后,基于人群的生存获益研究还很缺乏。本研究考察了免疫疗法前和免疫疗法时期NSCLC患者的总生存期(OS)和癌症特异性生存期:本研究使用了监测、流行病学和最终结果数据库,该数据库涵盖了 2000 年至 2020 年间的 17 个登记处。研究划分了两个队列:免疫治疗前(2010-2014年)和免疫治疗(2015-2020年),这两个队列与nivolumab的批准时间一致:该研究共纳入191802名患者,其中90807名患者在免疫治疗前阶段,100995名患者在免疫治疗阶段。从Kaplan-Meier曲线可以看出,免疫治疗时代的患者生存率明显更高(1年生存率为40.1% vs. 33.5%;3年生存率为17.8% vs. 11.7%;5年生存率为10.7% vs. 6.8%;中位生存期为8个月 vs. 7个月;P 结论:免疫治疗时代的患者生存率明显高于前者:总之,自从引入免疫疗法以来,转移性 NSCLC 患者的生存率有所提高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer
Cancer 医学-肿瘤学
CiteScore
13.10
自引率
3.20%
发文量
480
审稿时长
2-3 weeks
期刊介绍: The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信